Total Funding
50
Total FundingPost-IPO Debt raised
Growth Score
pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
51141
Mersana Therapeutics develops novel antibody-drug conjugates (ADCs) designed to treat cancer.
Acquired by 
Day One Biopharmaceuticals
David R. Elmaleh: FounderPast Role: FluoroPharma, Founder and Chief Scientific Advisor
Timothy B. Lowinger: Chief Science & Technology OfficerPast Role: Bayer HealthCare, Various
About the Company
Mersana Therapeutics develops novel antibody-drug conjugates (ADCs) designed to treat cancer. The company’s platforms, Dolasynthen (cytotoxic payloads) and Immunosynthen (immunostimulatory payloads), enable the creation of tailored ADCs for specific cancer targets. Its pipeline features wholly owned and partnered candidates, including Emi-Le
(emiltatug ledadotin; XMT-1660) targeting the protein B7-H4, and XMT-2056, which targets a novel epitope of the HER2 receptor. Mersana supports collaborations with other biopharmaceutical organizations to extend its ADC technology into additional indications.
Women Led
